With continued treatment, the incidence of gout flares decreased, but the overall incidence during weeks 9 through. Regarding safety, the incidence of adverse events was less using febuxostat 120 mg qd than allopurinol or febuxostat 40 mg qd or of febuxostat 120 mg qd vs. Febuxostat may be better than allopurinol in lowering urate. Pivotal trials with febuxostat compare monotherapy with the production inhibitor allopurinol vs monotherapy with the production inhibitor. Intensive urate lowering therapy of febuxostat compared to. Clinical trials febuxostat vs allopurinol three rct in patients with gout and serum uric acid level. To assess the comparative effectiveness of febuxostat and allopurinol in reducing serum urate sua levels in a realworld u. Uloric febuxostat dosing, indications, interactions. Gout, an arthritic disease having hall mark of affecting the metatarsophalangeal mtp joint, the joint of great toe to the foot. Comparative efficacy and safety of uratelowering therapy for.
However, few studies have examined the longterm efficacy and tolerability of febuxostat after switching from allopurinol in hemodialysis hd patients. Median exposure to study treatment was about 2 years. The confirms study reported comparable efficacy of febuxostat 40 mg compared with allopurinol 300 mg febuxostat 40 mg. Successful treatment of refractory gout using combined. Pdf febuxostat compared with allopurinol in patients with. Pdf the uratelowering efficacy and safety of febuxostat in the.
The median reduction in tophus area was 83 percent in patients receiving 80 mg of febuxostat and 66 percent in those receiving 120 mg of febuxostat, as compared with 50 per. When initially started, medications such as nsaids are often recommended to prevent gout flares. The most common doses were 300 mgday or lower dose for allopurinol and 40 mgday for febuxostat. Comparing febuxostat to allopurinol in the treatment of. Of patients taking febuxostat at 40 or 80 mg daily, 45% and 67%, respectively, reached the primary endpoint compared with 42% of those taking allopurinol 200300 mg daily. Subject is unable to take either of the protocolrequired gout flare prophylactic medications nsaid or colchicine due to contraindications or intolerance, e. According to the authors of comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout. Therefore, the present study evaluated the longterm efficacy and tolerability of febuxostat in hd patients after switching from allopurinol. Febuxostat 80 mg and 120 mg were more efficacious than allopurinol 100 to 300 mg, and febuxo stat 40 mg and allopurinol were comparable in uratelowering efficacy. Allopurinol and its metabolites are structural analogues of both purines and pyrimidines and thus can affect enzymes in both purine and pyrimidine metabolic pathways, whereas febuxostat is a nonpurine inhibitor of xo only. The trial, known as cares nct01101035 and supported by the maker of uloric febuxostat, randomized 6190 patients with gout and cvd from 320 north american sites to receive febuxostat or allopurinol. The study authors evaluated the efficacy and safety of febuxostat compared with allopurinol.
Allopurinol two common very common prescriptions for gout and how they work. Cardiovascular risks of febuxostat and allopurinol, compared. This is primarily where allopurinol and febuxostat are different. There was no significant difference in the rate of achievement of the target serum ua level gout. Febuxostat and allopurinol combination works better in gout. A 28week, phase iii, randomized, doubleblind, parallelgroup trial. Switching from allopurinol to febuxostat for the treatment of. Febuxostat compared with allopurinol in patients with hyperuricaemia and gout. Cardiovascular safety of febuxostat or allopurinol in.
Febuxostat is the first new xanthine oxidase inhibitor since allopurinol and was. There are a limited number of licensed treatments available. Pdf febuxostat compared with allopurinol in patients. The differences in the mechanisms of action between. Comparison of febuxostat and allopurinol for hyperuricemia. Colcrys colchicine is a secondchoice treatment for gout attacks. Mar 12, 2018 the trial, known as cares nct01101035 and supported by the maker of uloric febuxostat, randomized 6190 patients with gout and cvd from 320 north american sites to receive febuxostat or allopurinol. The safety of febuxosta t at all doses was comparable. Mortality risks higher with febuxostat vs allopurinol.
Potency on lowering serum uric acid in gout patients european. Compare allopurinol vs febuxostat headtohead with other drugs for uses, ratings, cost, side effects, interactions and more. Febuxostat can be given with or without meals or antacids. Uloric febuxostat is a medication you take once daily for gout, but it takes a few weeks to kick in. Listing a study does not mean it has been evaluated by the u. Febuxostat, sold under the brand names uloric among others, is a medication used longterm to treat gout due to high uric acid levels.
Comparative efficacy and safety of uratelowering therapy. Research shows febuxostat is more effective than allopurinol in reducing serum urate levels in patients with gout. Febuxostat the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. When in accumulated amounts, uric acid tends to form monosodium urate crystals that localize around the joints and periarticular tissue. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. Background and study aims gout is a condition in which small crystals of uric acid form inside and around the joints, causing pain and swelling. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout.
The febuxostat versus allopurinol controlled trial f act was a 52 week randomized, doubleblind, multicenter clinical trial that compared the safety and. May 17, 20 clinical trials febuxostat vs allopurinol three rct in patients with gout and serum uric acid level. It is generally recommended only for people who cannot take allopurinol. The fda safety alert underscores the need for shared uratelowering therapy decision making between clinicians and patients with gout, which should include a discussion on the cv.
We look forward to using this networkbased statistical method to combine findings from individual studies and provide useful information for. Febuxostat is the first new xanthine oxidase inhibitor since allopurinol and was licensed for use in 2008. The aim of this study is to compare the safety of febuxostat and allopurinol two drugs commonly used for gout when taken for an average of 3 years. Comparative efficacy and safety of uratelowering therapy for the. Colchicine is the specific drug in acurte phase along with a nsaid such as naproxen. The proportion of patients with sua febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. Oct 06, 2015 febuxostat is a novel xanthine oxidase inhibitor. To test the hypothesis that allopurinol is noninferior to febuxostat in the treatment of gout, the investigators propose a randomized openlabel noninferiority trial, which for the first time compares allopurinol with febuxostat using appropriately titrated. Comparing febuxostat to allopurinol in the treatment of gout. Compare headtohead ratings, side effects, warnings, dosages, interactions and.
Febuxostat is a new nonpurine xanthine oxidase inhibitor that is more potent than allopurinol 300 mg daily. The target is to get the urate level something below 6mg%. Zyloprim allopurinol works well to prevent gout attacks and is cheaper than some alternatives, but it takes a few weeks to start working. Be careful how much you use since it can cause problems with your blood. Combined allopurinol, febuxostat, and benzbromarone therapy reduced the urate level to gout. Switching from allopurinol to febuxostat for the treatment.
Febuxostat comes in oral tablets while allopurinol comes in oral tablets as well as an intravenous solution. The primary outcome was achieved by 53% of patients receiving 80 mg of febuxostat, 62% of those receiving 120 mg of febuxostat, and 21% of those receiving allopurinol p febuxostat group vs the allopurinol group. Alternatives to febuxostat treatment that are often effective include allopurinol dose escalation and uricosuric therapy alone or in combination with allopurinol. Jul 16, 2015 any contraindication to febuxostat or allopurinol with reference to the summary of product characteristics. Allopurinol two common very common prescriptions for gout and how they work gout is a form of inflammatory arthritis that is caused by hyperuricaemia or high amounts of uric acid in the blood. While not specifically related to the mechanism of action in gout, febuxostat, unlike allopurinol, is a substrate of uridine diphosphate glucuronosyltransferase ugt 1a1, 1a3, 1a9, 2b7 and cytochrome p450 cyp 1a2, 2c8, and 2c9.
Treat to target in gout by combining two modes of action. In febuxostat 40 mg, febuxostat 80 mg, and allopurinol groups, primary. None of the excipients in the febuxostat blend are of animal origin. This retrospective study utilized 2009 to 2012 medical and pharmacy claims and laboratory data from a large u. Comparative efficacy and safety of febuxostat and allopurinol. There was no significant difference in ua between the 2 groups before the start of treatment 8. Compare allopurinol vs febuxostat comprehensive analysis by. In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 months maximum, 85 months.
Febuxostat, allopurinol, gout, metaanalysis introduction hyperuricemia is defined as a serum urate sua level exceeding the limit of urate solubility 6. Background febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout. Gout is a form of inflammatory arthritis that is caused by hyperuricaemia or high amounts of uric acid in the blood. A threearm trial compared allopurinol, febuxostat and placebo.
May, 2015 febuxostat treated patients were permitted an index medication dose of 40 mg or 80 mg the only 2 available doses. Febuxostat compared with allopurinol in patients with. Pdf febuxostat for the treatment of hyperuricaemia in gout. In two phase iii trials, significantly more febuxostattreated gout patients met the primary endpoint serum urate sua febuxostat vs. How does allopurinol influence more than xo activity. Febuxostat and allopurinol combination works better in. The longterm management of gout requires reduction of serum urate levels and this is most often achieved with use of xanthine oxidase inhibitors, such as allopurinol. Febuxostat adenuric for chronic symptomatic gout nps. Use of newly available febuxostat in a case of chronic.
Compare allopurinol vs febuxostat comprehensive analysis. Comparison of febuxostat and allopurinol for hyperuricemia in. Combined allopurinol, febuxostat, and benzbromarone therapy reduced the urate level to oct 19, 2015 gout. A total of 6190 patients with gout and cardiovascular disease from 320 centers in north america were randomly assigned to receive febuxostat, a nonpurine xanthine oxidase inhibitor, or allopurinol. Common side effects include liver problems, nausea. Jun 21, 2010 at the patients final clinic visit, 75% of those treated with febuxostat 80 mgday achieved uratelowering to a goal of less than 6 mgdl, but only 38% of patients taking allopurinol 300 mgday achieved that goal p apr 14, 2017 febuxostat vs allopurinol.
Any contraindication to febuxostat or allopurinol with reference to the summary of product characteristics. Jul 22, 2014 there was no significant difference in the rate of achievement of the target serum ua level febuxostat group vs 50 % in the allopurinol group, p 0. Febuxostat vs allopurinol and placebo in subjects with hyperuricaemia and gout. In a study comparing between febuxostat 40 mgday, 80 mgday and allopurinol 300 mgday, in which 65 percent of subjects in each of the treatment group had mild or moderate renal impairment, febuxostat at either dose was shown to be more effective than allopurinol in.
1039 278 362 150 133 383 326 891 51 377 1422 1072 506 1144 438 394 1106 1398 900 903 604 1190 1258 1025 899 1156 706 1216 638 427 410 842 841 272 604 387 1458 1148 1265 749 983 824 1457 857 1106 361 1080 608 1472 776